Related Experiment Video
Updated: Jun 20, 2026
07:41
Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
Published on: February 8, 2022
4.2K
ACC/AHA vs ESC/EACT Guidelines on valvular heart disease: EJPC Guideline comparison review
Maciej Debski1,2, Vasiliki Tsampasian1,2, Joseph Zacharias3
1Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, United Kingdom.
European Journal of Preventive Cardiology
|January 12, 2026
Summary
Comparing 2025 European and American guidelines for valvular heart disease reveals key differences in intervention timing and transcatheter therapies. These updates guide clinical decisions and future research priorities.
Area of Science:
- Cardiology
- Clinical Decision-Making
- Medical Guidelines
Background:
- Valvular heart disease management presents ongoing clinical challenges.
- International guidelines from the American College of Cardiology/American Heart Association (ACC/AHA) and European Society of Cardiology/European Association for Cardio-Thoracic Surgery (ESC/EACTS) offer frameworks for treatment.
- Recent updates in 2025 highlight evolving practices.
Purpose of the Study:
- To compare the latest international guidelines for valvular heart disease management.
- To identify consistencies and discrepancies between the ACC/AHA and ESC/EACTS guidelines.
- To highlight areas for future research in valvular heart disease.
Main Methods:
- Comparative analysis of the 2025 ACC/AHA and ESC/EACTS guidelines.
- Review of new trial evidence incorporated into the European guidelines.
- Identification of key divergences in recommendations.
Main Results:
- Broad agreement exists on intervention principles, prosthesis selection, and the role of Heart Teams.
- Significant differences noted in thresholds for earlier intervention in aortic stenosis and regurgitation.
- Expanded recommendations for transcatheter edge-to-edge repair, mitral valve replacement, and tricuspid repair/transcatheter therapies are present.
- Evolving strategies for coronary assessment in transcatheter aortic valve implantation and sex-specific considerations are highlighted.
Conclusions:
- The 2025 ESC/EACTS guidelines incorporate substantial new trial evidence, leading to key divergences from ACC/AHA recommendations.
- Discrepancies exist in intervention timing, transcatheter therapy indications, and specific procedural approaches.
- Future research should address these discrepancies and evolving aspects of valvular heart disease management.
Related Concept Videos
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...